Bextra Pennsylvania

Bextra® Pennsylvania. Lawsuits are being initiated in Pennsylvania due to new warnings about COX-2 anti-inflammatory drugs. Bextra® has added warnings to it's box strengthening previous warnings about the risk of life-threatening skin reactions and a new bolded warning contraindicating (not using) it for patients undergoing coronary artery bypass surgery. Now, a month later, the FDA has asked Bextra's maker Pfizer to remove it from the market.

If you are currently on Bextra check with your doctor, especially if you have a history of heart problems.

Withdrawal

On April 7, 2005 the FDA announced that it has asked Pfizer, Inc. to withdraw Bextra from the market "because the overall risk versus benefit profile for the drug is unfavorable."

It was prescribed for inflammation and pain from arthritis or menstrual cramping. Other drugs in this class include Celebrex® and Vioxx®. Bextra® and Celebrex® are both marketed by Pharmacia Corporation and Pfizer and Vioxx® is manufactured by Merck. Doctors switched patients from Vioxx® to Bextra® when Merck voluntarily removed it from the market due studies showing an increased risk for heart attack and stroke.

bextra site map

Attorney Information	FDA Information
For a free case evaluation from a Pennsylvania attorney, click here: lawforum	Click here to read the FDA questions and answers about strengthened warnings on Bextra® boxes.
Munley, Munley & Cartwright, P.C. is a Pennsylvania law office which has breaking news and information about this lawsuit	To report any unexpected adverse or serious events associated with the use of Bextra® contact the FDA MedWatch program on the internet or at 1-800-FDA-1088

Autism Education Materials!